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Survivin protein is a metalloprotein member of the inhibitors of apoptosis proteins family, involved in the
regulation of programmed cell death. Due to the recent development of antitumor therapies having survivin as
molecular target, several strategies to interfere with the expression or function of survivin have emerged. This
work describes the discovery of a new potential inhibitor of survivin function using a computer-aided drug design
approach. Structure-based virtual screening and molecular dynamic simulations were carried out to select two
compounds as possible inhibitors. According to the binding energy, possible ligand localization is in a cavity, close
to dimerization interface. Next, cell-based assays were performed on three cell lines: two with tumor phenotype
and over-expression of survivin, and another with normal phenotype and low expression of survivin. One of the
selected compounds shows a selectively antitumor effect on panel cell lines suggesting that the compound effect
could be correlated with the survivin expression.1. Introduction
Survivin protein (16,5 kDa) is a metalloprotein member of the in-
hibitors of apoptosis protein (IAP) family, involved in the regulation of
programmed cell death [1]. Encoded by the BIRC5 gene located at the
17q25 locus in humans [2]. Wild-type survivin protein has 142 amino
acids although there are variants of alternative splicing with a flexible
amount of amino acids and unknown functions [3].
The survivin structure has a single repetition of the BIR (Baculovirus
IAP repeat) domain of approximately 70 amino acids at its N-terminus,
characteristic of IAPs. Unlike other IAPs, it lacks the RING finger domain
carboxy-terminal and instead it has a long alpha-helix coil of 40 amino
acids and 65Å involved in the association of the protein with the mi-
crotubules during the G2/M phase of the cell cycle. This domain is key to
the interaction with the components of the chromosomal passage com-
plex, during late mitosis [4, 5]. Regarding its behavior, crystallographic
studies have shown that it forms homodimers across the interface of
dimerization, which includes the residues 6–10 and 89–102. The dimeric
structure is stabilized by the formation of non-polar contacts between
residues, mostly hydrophobic, with a total contact area between mono-
mers of around 500Å2 [4, 6]. It is expressed mainly in embryonic tissues
[2] and has a significant role in regulation of cell division and cellr (M.J. Lavecchia), ileon@biol.un
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is an open access article under tsurvival [4, 7, 8]. However, its expression levels decrease during devel-
opment, being undetectable in terminally differentiated normal tissues
[2, 5]. Nevertheless, survivin expression is upregulated in many types of
tumors in which increases cell survival and tumor progression, mainly
due to the inhibition of apoptosis [9]. Additionally, upregulation of
survivin correlates with a poor response to chemotherapy and a poor
clinical prognosis in patients with lung, bone, colon, breast, and stomach
cancer [10, 11].
Otherwise, downregulation of survivin expression is related to an
increase in the activity of caspase-3 and enhanced apoptosis in human
cervix cancer cell line [5, 7]. In addition, downregulation of survivin
expression has been shown to enhance the efficacy of cytotoxic drugs,
increasing the sensitivity of tumors cells on in vitro and in vivo conditions
[12, 13, 14]. This shows the relevance of the development of anti-tumor
therapies by selecting survivin as molecular target.
In recent years, several strategies have been developed to interfere
with the expression or function of survivin, among which the use of small
interfering RNA, antisense oligonucleotides, dominant-negative mutant,
vaccine-based therapies and use of small molecules inhibitors [15, 16].
For example, Mir-335 [17] and LY2181308 are small interfering RNAs
that destabilize survivin mRNA and induce its degradation [18]. More-
over, different small molecules as YM155 [19, 20, 21] and FL118 [18,22]lp.edu.ar (I.E. Leon).
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Fig. 1. Schemes of the molecules included in the docking validation that are known to have interaction with survivin.
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ment of inhibitors that interact directly with the protein emerged. This
has been a challenge since survivin is considered a “non-druggable”
protein for not having catalytic activity or natural ligands, and its func-
tion is mediated by protein-protein interactions [23, 24, 25]. However,
some ligand-binding sites in survivin have been proposed for the inhi-
bition of their function, established through affinity-based techniques
and in-silico methods [26, 27, 28]. In this sense, the small molecule
Abbott8 (Fig. 1) was identified by high-throughput screening (HTS),
which interacts with a cavity, next to the dimerization interface [29, 30].
In addition, structural analogues of Abbott8 (LLP3, LLP6, LLP9, see
Fig. 1) exhibited antitumor activity [28] and docking studies have shown
that these compounds also interact in this cavity. Also, Berezov et al.
reported novel ligands (S2, S10, S12, see Fig. 1) that interact in the
cavity, slightly further away from the dimerization interface with respect
to Abbott. S12 has shown in vitro and in vivo antitumor activity in
cancer cell lines that overexpress survivin and in xenographic pancreatic
models [27]. Berezov et al. proposed this cavity as a binding site for the
potential ligands capable of inducing allosteric conformational changes
and modulating the function of survivin. On the other hand, LQZ-7 and
derivative compounds (LQZ-7B, LQZ-7C and LQZ-7F) (Fig. 1) have been
shown effectively to disrupt the dimer form of survivin and induce pro-
grammed cell death and inhibition of proteasome activity [26]. In this
case, Qi et al. proposed using docking that the interaction occurs in the2
dimerization interface.
Here, we describe the discovery of new potential inhibitors of survi-
vin function, using a computer-aided drug design approach. Structure-
based virtual screening (SBVS) and molecular dynamics were carried
out to select two compounds as possible inhibitors. Next, cell-based as-
says were performed on three cell lines: two with tumor phenotype and
over-expression of survivin, and another with normal phenotype and low
expression of survivin. Finally, one of the selected compounds,
ZINC2243688, shows a selective antitumor effect on panel cell lines
suggesting that the compound effect could be correlated with survivin
expression.
2. Materials and methods
2.1. Materials
Tissue culture materials were purchased from Corning (Princeton, NJ,
USA), Dulbecco's modified Eagle's medium (DMEM) and TrypLE TM were
purchased from Gibco (Gaithersburg, MD, USA), and fetal bovine serum
(FBS) was purchased from Internegocios (Argentina).
2-(3-hydroxyphenyl)benzo[h]chromen-4-one (ZINC57885) and
(1S,3R)-3-((((9H-Fluoren-9-yl) methoxy)carbonyl)amino)cyclopentan-
ecarboxylic acid (ZINC2243688) were purchased from Sigma (St. Louis,
MO, USA).
Fig. 2. Detailed view of dimerization interface (above) and hydrophobic cavity (below).
Fig. 3. Chemical structures of molecules selected by virtual screening: (1S,3R)-3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)cyclopentanecarboxylic acid
(ZINC2243688) and 2-phenylbenzo[h]chromen-4-one (ZINC57885).
P.A. Quispe et al. Heliyon 5 (2019) e02238The MG-63 human osteosarcoma cells (CRL1427), A549 human lung
adenocarcinoma cells (CCL-185) and MRC-5 human fibroblast (CCL-171)
were purchased from ATCC.
2.2. Preparation of the molecular systems
The simulations were based on survivin monomer extracted from
dimeric X-ray crystal structure (PDB ID: 1F3H and 1E31). Survivin3
preparation was done with Molprobity [31]. Water molecules and other
ligands were removed. All Asp and Glu residues were considered to have
a negative charge and all the Arg and Lys residues were considered to
have a positive charge. Histidine tautomers were assigned following the
hydrogen bonding pattern. Compounds shown in Fig. 1, taking into ac-
count that these molecules have inhibitory capacity measured experi-
mentally against survivin, were taken as active reference ligands. Their
structures were sketched using Avogadro molecular editor [32] or
Table 1
Docking score of survivin complexes obtained with Autodock Vina for interface
and cavity sites, using 1F3H and 1E31 X-ray structures as targets.
Ligands Interface Cavity
1F3H 1E31 1F3H 1E31
ABBOTT8 -6.7 -6.9 -8.8 -8.5
LLP3 -7.1 -7.0 -10.8 -9.7
LLP6 -6.3 -6.8 -9.0 -9.1
LLP9 -6.9 -7.2 -9.7 -8.5
LQZ-7B -7.3 -6.6 -9.3 -9.1
LQZ-7C -5.7 -7.6 -9.5 -8.5
LQZ-7F -6.9 -7.1 -8.0 -8.3
S10 -7.0 -7.5 -8.9 -8.1
S12 -6.7 -7.2 -7.9 -8.2
S2 -7.9 -7.9 -9.6 -8.3
ZINC2243688 -7.0 -7.4 -7.5 -8.1
ZINC57885 -7.6 -7.7 -7.9 -8.1
Table 2
Lowest binding free energies of compounds and standard deviation, between
parentheses, in the dimerization interface and cavity calculated usingMM/GBSA.
Compound ΔGMMGBSA (Kcal/mol)
Dimerization interface Cavity
S12 -11.1 (2.4) -35.6 (2.5)
LQZ-7F -17.9 (2.1) -29.1 (2.8)
ZINC2243688 -13.2 (2.7) -39.4 (2.9)
ZINC57885 -21.4 (2.4) -31.4 (3.0)
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semiempirical method [34], implemented in Mopac [35].
2.3. Molecular docking studies
Molecular docking was carried out to find and score protein-ligand
binding poses on a survivin monomer (PDB ID 1F3H:A and 1E31:A)
with Autodock Vina [36]. Ligands were docked using a
flexible-ligand/rigid-receptor approach. A docking box (30.00 Å  24.75
Å x 24.00Å, centered in Phe93) was selected to include binding sites
mentioned above: dimerization interface and close cavity.
In order to assess the performance of the docking methodology, the
area under the receiver operating characteristic curve (ROC AUC) and
enrichment factor were calculated. DUD-E [37] was used for generation
of decoys from reference active compounds. This server generates 50
decoys for every active provided, with input and output being in SMILES
format. The decoys generated were downloaded from ZINC chemical
database [38].
For the purpose of applying structure-based virtual screening (SBVS),
Sigma Aldrich (Building Blocks) subset was also downloaded from ZINC.
The post-docking analysis included score comparisons of the evalu-
ated compounds respect references and the visualization of the ligand-
receptor complexes with Pymol [39] to analyze the potential in-
teractions with the amino acid components of the dimerization interface.
2.4. Molecular dynamics (MD) simulations
The best poses of selected and reference compounds obtained by
docking, in the dimerization interface and in the cavity of survivin in
monomeric form, were submitted to a MD simulation. The complexes
have a negative net charge, sodium cations were added as counterions
with Leap module to achieve electroneutrality. The neutralized com-
plexes were immersed in a box of TIP3P waters which extended up to 12
Å from the solute. Receptors were described using the Amber14SB force
field [40]. Zinc AMBER force field (ZAFF) [41] was used to describe zinc
cation and neighboring residues. Ligands were described using the
Generalized Amber Force Field (GAFF) [42] with charges derived from4
restrained electrostatic potential (RESP) approach, which were calcu-
lated with Antechamber module and Gaussian03 [43]. Leap and Ante-
chamber are included in the package AmberTools 16.0 [44].
All MD simulations were run using the NAMD 2.12 software [45]. The
van der Waals interaction cutoff distances were set at 12 Å and
long-range electrostatic forces were computed using the particle mesh
Ewald summation method with a grid size set to 1.0 Å. The 1–4 contri-
butions were multiplied by a factor of 0.83 to match the AMBER force
field requirements. Prior to simulations, the systems were subjected to a
minimization step: first only the ligand and the water molecules were
minimized, then extended to the side chains and, finally to the entire
system. MD began by heating from 0 to 300 K over 30 ps and the MD was
continued for a total simulation time of 25 ns. Constant temperature (300
K) was maintained using Langevin dynamics with a damping coefficient
of 5 ps1, while pressure was kept constant at 1 atm through the
Nose-Hoover Langevin piston method with a decay period of 200 fs and a
damping time constant of 100 fs. A time step of 1 fs was adopted for all
simulations,. Bonds involving hydrogen atoms of waters were con-
strained using the SHAKE algorithm [46]. RMSD values were depicted as
a line-style plot to determine the convergence and stability of simulations
(Figs. S1, S2 and S5).
2.5. MM/GBSA calculations
Ligand-survivin binding free energies were computed using the MM/
GBSA method for all complexes, where the binding free energy is
calculated as the difference between the bound and unbound states of
protein and ligand [47, 48].
The entropic changes were calculated using quasi-harmonic approx-
imation. The solvation free energy (ΔGsolv) was separated into polar and
non-polar contributions. The polar contribution toΔGsolv was calculated
using the generalized Born (GB) model [49] implemented inMMPBSA.py
module [50], igb¼ 3 as selected model. The hydrophobic contribution to
ΔGsolv was determined using the solvent-accessible surface area (SASA).
The protein–ligand binding free energy was calculated using a single
trajectory (for ligand, receptor and complex) based on 1000 snapshots
taken from the last 10 ns portion (10 ps interval) of the MD simulation
trajectories.
For the purpose of obtaining the detailed representation of the li-
gands/survivin interactions, free energy decomposition analysis was
employed to decompose the total binding free energies into
ligand–residue pairs. These calculations were performed using a pairwise
energy decomposition scheme (idecomp option 3) also with the
MMPBSA.py module. In this scheme, interactions are decomposed by
specific residue pairs by including only those interactions in which one
atom from each of the analyzed residues is participating, following the
work of Gohlke et al.[51].
2.6. Cell lines and growth conditions
MG-63 human osteosarcoma cells (CRL1427), A549 human lung
adenocarcinoma cells (CCL-185) andMRC-5 human fibroblast (CCL-171)
were grown in DMEM containing 10 % FBS, 100 U/mL penicillin, and
100 μg/mL streptomycin at 37 C in a 5% CO2 atmosphere. Cells were
seeded in a 75 cm2 flask, and when 70–80 % of confluence was reached,
cells were subcultured using 1 mL of TrypLE TM per 25 cm2 flask. For
experiments, cells were grown in multiwell plates. When cells reached
the desired confluence, the monolayers were washed with DMEM and
were incubated under different conditions according to the experiments.
2.7. Cell viability assay: 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay was performed according to Mosmann [52]. Briefly, cells
were seeded in a 96-well dish, allowed to attach for 24 h, and treated
Fig. 4. Poses of selected ligands in the dimerization interface of survivin protein obtained from molecular dynamics.
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the medium was changed and the cells were incubated with 0.5 mg/mL
MTT under normal culture conditions for 3 h. Cell viability was marked
by the conversion of the tetrazolium salt MTT to a colored formazan by
mitochondrial dehydrogenases. Color development was measured spec-
trophotometrically with a microplate reader (model 7530, Cambridge
Technology, USA) at 570 nm after cell lysis in DMSO (100 μL per well).
Cell viability was plotted as the percentage of the control value.
3. Results and discussion
3.1. Structure-based virtual screening
To validate the docking method, receiver operating characteristic
(ROC) curve and enrichment factor (EF) were calculated using Screening
Results Analysis Online [53] based on the Autodock Vina score for active
ligands and decoys on survivin target (PDB ID: 1F3H). ROC AUC value
was 0.898, which shows a good docking performance. In general, an AUC
of 0.5 suggests no discrimination (i.e., ability to discriminate active
molecules from decoys), while an area of 1 reflects a perfectly accurate
test. Enrichment factors were 4.7 (EF%2)/7.4 (EF%5). ROC curve is
showed in Fig. S3. Decoys and reference ligands with their scores are
listed in Table SI of Supporting Information.
It should be clarified that for S12 and related compounds, based on
literature search, it is not established which of the enantiomers is the5
active against survivin, and the drug is marketed as racemic mixture. For
this reason both enantiomers were tested. Based on molecular dynamics
results, see below, only the S enantiomer was included in ROC curve
analysis.
Results analysis shows that the best poses of ligands and decoys locate
mainly in a cavity, which is composed principally by residues Arg18,
Glu40, Phe86, Val89 and Lys91. This location was also observed for the
compounds reported by Qi et al. [26], LQZ-7 and its analogs which had
been reported as located in another site, the dimerization interface. A
detailed description of both sites is depicted in Fig. 2. It should be notice
that virtual screening was carried out with one of the monomers, chain A.
Another chain has been included in the figure to facilitate the
description.
A virtual screening was performed on Sigma Aldrich catalog, included
in ZINC database, with the aim of identifying new potential inhibitors of
human survivin. Two compounds were selected from those that showed
better affinity according to the virtual screening results, even out-
performing the reference compounds, based on observation and feasi-
bility of acquisition: 2-(3-hydroxyphenyl)benzo[h]chromen-4-one
(ZINC57885) and (1S,3R)-3-((((9H-Fluoren-9-yl) methoxy)carbonyl)
amino)cyclopentanecarboxylic acid (ZINC2243688) (see Fig. 3).
In order to compare and analyze the interaction of reference com-
pounds and selected compounds with the cavity and the dimerization
interface, dockings limited to each of these regions were performed.
The results of molecular docking showed that the best scored poses,
Fig. 5. Poses of selected ligands in cavity of survivin protein obtained from molecular dynamics.
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tioned in cavity (Table 1).
In addition, to analyze if conformational variations in the receptor
could change the trend and increase the number of poses located in the
dimerization interface, rotamers were generated with Autodock Vina for
residues Trp10, Phe13, Phe58, Phe86, Val89, Phe93, Glu94, Leu96,
Gln92, Leu98 and, Phe101. Except for ZINC57885, which was more
inserted in the cavity (pose then discarded based on MM/GBSA energy
results), the rest of ligands showed no significant changes in location and
Autodock Vina scores with respect to rigid receptor.
An additional crystalline structure of human survivin (PDB ID: 1E31)
was used also as target because it revealed some differences respect
1F3H, in particular Gln92, and this could affect the entrance of the ligand
in the cavity. It resulted that there were no appreciable differences be-
tween the targets, both in Autodock Vina score and in the structures of
the generated poses, so it was decided to continue only with 1F3H X-ray
structure.
3.2. Molecular dynamics and binding energies
MD simulation studies were then performed to study the binding
modes of these compounds. Considering the high computational cost to
run MD simulation, this technique was applied on LQZ-7F and S12,
which were taken as “extreme” ligand references, located by authors in
the dimerization interface and the cavity sites, respectively. ZINC57885
and ZINC2243688were also studied with MD. Some poses, including the6
best scored from Autodock Vina of each region, were selected and sub-
mitted to a MD with 25ns of molecular dynamic simulation. From frames
extracted from last 10ns of these trajectories, and using the MM-GBSA
model, binding energies were estimated for these ligands, see Table 2.
The most stable poses found for the dimerization interface and cavity
sites are shown in Fig. 4 and Fig. 5, respectively. It is observed that in
both the reference ligands and in the compounds selected by virtual
screening, the binding energy is more favorable in the cavity with respect
to the dimerization interface. This result agrees with the trend obtained
by docking.
For the dimerization interface, energy contributions per residue to the
energy binding using MM/GBSA are shown in Fig. 6, this allows an
interpretation of the contributions to the total interaction energy
(Table SII shows mean distance between ligands and residues over the
last 10 ns of molecular dynamic simulation).
Interactions established by LQZ-7F and survivin were in agreement
with reported by Qi et al. [26]: π-π stacking and hydrophobic interaction
between the tetracyclic furazanopyrazine ring of LQZ-7F and the hy-
drophobic residues Trp10, Phe93, Leu98 and Phe101, the last two
considered core residues of the dimerization interface; H-bond between
the primary amine group of LQZ-7F and Glu94 of surviving. In our re-
sults, an additional interaction with Leu96 is observed.
ZINC57885 and ZINC2243688 binding modes analysis revealed in-
teractions between ligands with the core residues of the dimerization
interface: the naphthyl and phenyl groups of ZINC57885 and the fluo-
renyl ring system of ZINC2243688 establish π-π stacking interactions
Fig. 6. Plot of MM/GBSA binding free energy contribution per residue of the complexes in the dimerization interface site, calculated with MMPBSA.py.
Fig. 7. Plot of MM/GBSA binding free energy contribution per residue of the complexes in the dimerization interface site, calculated with MMPBSA.py.
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interact with residues Trp10 and Leu96.
In the cavity, contributions per residue to the energy binding were
also calculated and are showed in Fig. 7 (Table SIII shows mean distance7
between ligands and residues over the last 10 ns of molecular dynamic
simulation). The ligands, with the exception of ZINC57885, are stabi-
lized by hydrogen bond interactions (conventional or carbon-hydrogen
bond) with one or more of residues Arg18, Glu40, Val89 or Gln92.
Fig. 8. Effects of ZINC2243688 on cell viability of human normal fibroblast
(MRC-5), human lung adenocarcinoma (A549) and human bone osteosarcoma
(MG-63).
P.A. Quispe et al. Heliyon 5 (2019) e02238Also, only for ZINC2243688, a hydrogen bond interaction is observed
with Phe93 through the carboxylic acid.
A special mention deserves S12 case. Poses of both S12 enantiomers
were obtained by docking and subjected to molecular dynamics andMM/
GBSA calculations. S enantiomer showed to be 21.3 kcal mol⁻1 more
stable than R enantiomer in the cavity. According to the energy decom-
position per residue, see Fig. S4, S12(S) establishes interactions by
hydrogen bond with residues Arg18, Glu40, and Gln92. However,
S12(R) is unable to establish interactions with Arg18 and Glu40 because
hydroxyl group of oxindole is located away from these residues and
opposite in the plane. Hydrophobic contacts with side chains of Phe13,
Phe86, Val89, Leu96, and Phe93 do not change significantly between
both enantiomers. Mean distances between this residues and enantio-
mers, showed in Table SIII, agree with these observations. Furthermore,
Berezov et al. [27] have experimentally verified that S12 is not capable of
interacting with survivin mutants (F86A and V89T). To evaluate if the
modeled system complied with experimental observations, both mutated
survivin were prepared and subjected to the same protocol (minimiza-
tion, heating, equilibration). The binding energy of S12(S) with the
mutated survivins F86A and V89Twas less favorable compared to theWT
protein (ΔΔGbind 13.7 kcal mol⁻1 and 7.5 kcal mol⁻1 respectively), which
agrees with the experimental results. Based on energy decomposition per
residue, see Fig. S6, the interactions most affected by these mutations
were hydrogen bonds: magnitude of such interactions with Arg18, Glu40
Gln92 decrease respect to WT. In both cases, the oxindole group un-
dergoes a position change. On the other hand, interaction pattern of
S12(S) with hydrophobic residues of survivin-F86A was similar to that
observed for survivin-WT, with the exception of Phe93 in which a π-π
stacking interaction is observed with the 3-hydroxyindole. In
survivin-V89T case, S12(S) shows less interaction with most of hydro-
phobic residues, with the exception of Phe86, which establishes a strong
π-π stacking interaction with benzo [1, 3]-dioxolyl group.3.3. Cytotoxicity assays
In order to evaluate the antitumor activity and selectivity of the
selected compounds and with the intention to corroborate the predicted
effect from the in silico studies, the human tumor cell lines with over
expression of survivin A549 (lung) and MG-63 (bone) and the non-
cancerous cell line (MRC-5) were selected. They were treated with
ZINC57885 and ZINC2243688 at different concentrations to compare
the sensitivity.
Fig. 8 shows the anticancer activity of ZINC2243688 on three cell
lines. The data presented herein show a cytotoxic effect of ZINC2243688
in a concentration-dependent manner from 100 to 400 μM on A549 and
MG-63 with statistically significant differences versus the control (p <8
0.01).
Nevertheless, this compound only shows slight cytotoxicity effects on
normal MRC-5 cells suggesting that has a very good correlation in the
effects over normal and tumor cells. In this sense, it was observed that cell
lines with overexpression of survivin were much more sensitive to the
deleterious effect of the treatment with ZINC2243688 respect to the non-
cancerous line.
On the other hand, it should be clarify that problems with
ZINC057885 solubility in the cell culture medium was a main factor that
limited the studies carried out with this compound (Results are not
shown).
4. Conclusions
In this work, we have identified a potential lead inhibitor
(ZINC2243688) that could bind to survivin in a cavity close to the
dimerization interface. These findings were achieved using docking score
and MM/GBSA binding energies using trajectories of molecular dy-
namics. Using these techniques also, it was observed that interactions
between test ligands and survivin dimerization interface are possibly less
favorable with respect interactions with this cavity.
The conformational analysis and free energy profile per residue
calculated for S12 with survivin correlated with the experimental results
observed by Berezov et al. [27] In addition, based on the energy results,
the S enantiomer of S12 is proposed as the active isomer against survivin.
On the other hand, our results suggest that the interaction of LQZ-7
and its analogues with the survivin possibly occurs also in the cavity. This
result is in contrast to what was predicted by Qi et al. [26] This difference
possibly is due to the fact that these authors restricted the docking
analysis space to the dimerization interface region. It should be noted
that the energy difference between both locations (cavity and dimer-
ization interface) is not high respect to its standard error, so further
research should be carried out with other techniques to be conclusive.
Besides, ZINC2243688 diminished the cell viability on bone and lung
cancer cells showing a higher selectivity toward tumor than normal cells.
In this way, it was observed that cell lines that overexpressed survivin
(MG-63, A549) was much more sensitive to the deleterious action of
ZINC2243688 compared to the normal cell line (MCR-5) suggesting the
importance of survivin as molecular target in cancer therapies.
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